Beacon Biosignals

Beacon Biosignals (operating via beacon.bio) is a pioneering precision medicine and neurotechnology powerhouse engineered to accelerate drug development and fundamentally transform brain health diagnostics. Founded in 2019 by neuroscientists and practicing neurologists, and backed by top-tier investors including General Catalyst, the enterprise natively unifies its FDA 510(k)-cleared Waveband EEG headband with advanced AI algorithms to unlock quantitative biomarker discovery. Moving far beyond traditional, siloed clinical trials and cumbersome sleep facility assessments, Beacon Biosignals brings highly scalable, multi-night data collection directly into patients' natural sleep environments. The company powers the clinical development of novel therapeutics for neurological, psychiatric, and sleep disorders across full Phase 1-4 lifecycles. Their Clinico-EEG database—the world’s largest clinically validated neurodiagnostic dataset containing over 2 million hours of analyzed EEG data from nearly 100,000 patients—enables life-saving treatments to reach the right individuals faster. Under the hood, their technology core leverages a robust cloud-native analytics platform, precision machine learning architectures, and seamless asynchronous telemetry to execute large-scale RWD/RWE retrospective and predictive studies. Capturing massive market acceleration and partnering with leading pharmaceutical giants, Beacon Biosignals remains a definitive cornerstone of modern neurodiagnostic architecture, turning complex brain physiology into accessible, interpretable, and highly actionable healthcare solutions.